Infectious Disease Book

http://www.fpnotebook.com/

Fluoroquinolone

Aka: Fluoroquinolone, Quinolone, Nalidixic Acid
  1. Indications
    1. Cystic Fibrosis
    2. Complicated Urinary Tract Infection
    3. Enteric Fever
    4. Chronic Suppurative Otitis Media
    5. Multi-drug resistant Gram NegativeSepsis
    6. Multi-drug resistant Mycobacterium infection
    7. Skeletal infection caused by Gram Negatives
    8. Febrile neutropenic patients
    9. Bacterial Meningitis with resistant organisms
    10. Neisseria Meningitidis prophylaxis
    11. Otitis Media with patent Tympanostomy Tubes (drops)
    12. Bacterial Conjunctivitis (drops)
    13. Otitis Externa (drops)
  2. Contraindications: Relative
    1. Not FDA approved for use under age 18 years
      1. Theoretical cartilage growth suppression
    2. Increasing use in pediatric patients
      1. Quinolones have a long track record of use in children with Cystic Fibrosis
      2. Despite cartilage effects in study young dogs, no strong evidence of similar effects in children
      3. Consider for specific infections (pseudomonas aeruginosa) or resistant infections (e.g. Pneumonia, Sinusitis)
      4. Transient myalgias and Arthralgias may occur (however Quinolone induced Tendinopathy is rare in children)
      5. Bradley (2014) Pediatrics 134(1):e146-53 [PubMed]
  3. Precautions: FDA Warnings
    1. See adverse effects below
    2. Informed Consent regarding risk is recommended
      1. Avoid high impact while taking Fluoroquinolones
      2. Onset typically within first 1-2 weeks of exposure, but may be delayed up to 90 days
    3. Tendinopathy and tendon rupture risk (FDA Black Box Warning)
      1. Highest risk in age >60 years, males, Chronic Kidney Disease, and especially Corticosteroid use (RR:46)
    4. Peripheral Neuropathy (FDA warning in 2013)
      1. Potentially long-lasting, disabling complication
  4. Pharmacokinetics
    1. Oral dosing equivalent to intravenous
    2. Tissue penetration
      1. High tissue concentrations
        1. Stool and bile
        2. Prostate
        3. Lung
        4. White Blood Cells: Neutrophils, Macrophages
        5. Kidney and urine
      2. Low tissue concentrations (poor penetration)
        1. Poor cerebrospinal fluid penetration
    3. Excretion
      1. Renal excretion: Most Fluoroquinolones
      2. Hepatic excretion
        1. Sparfloxacin (Zagam)
        2. Moxifloxacin (Avelox)
        3. Trovafloxacin (Trovan)
  5. Pathophysiology: Bacterial Resistance Mechanisms
    1. Mutations of A Subunits of DNA gyrase
    2. Alterations of outer membrane porins
      1. Affects organism permeability
  6. Mechanism
    1. Gram Negative activity
      1. Inhibits DNA gyrase resulting in dsDNA fragmentation
    2. Gram Positive activity
      1. Inhibits DNA type IV topoisomerase
  7. Mechanism: Fluoroquinolone classes
    1. First Generation Quinolones
      1. Good Gram Negative Rod efficacy
      2. Useful in Urinary Tract Infection
      3. Example: Nalidixic Acid (introduced in 1962)
    2. Second Generation Quinolones
      1. Most active on Aerobic Gram Negative Rods
      2. Some Gram Positive coverage
      3. Example: Ciprofloxacin (Cipro)
    3. Third Generation Quinolones
      1. Broad Spectrum
        1. Gram Negative Rod coverage as above
        2. Greater Gram Positive Cocci coverage
          1. Especially Pneumococcus coverage
      2. Example: Levofloxacin (Levaquin)
    4. Fourth Generation Quinolones
      1. Very Broad spectrum
        1. Gram Negative Rod coverage
        2. Gram Positive Cocci coverage
        3. Anaerobes
      2. Less resistance development
      3. Example: Trovafloxacin (Trovan)
  8. Mechanism: Activity Spectrum
    1. Most Gram Negative Bacteria
      1. Best Fluoroquinolone Coverage
        1. Second Generation Fluoroquinolone
        2. Third Generation Fluoroquinolone
      2. Bacteria
        1. Enterobacteriaceae (Gram Negative Rods)
        2. Pseudomonas aeruginosa (especially Ciprofloxacin)
        3. HaemophilusInfluenzae
        4. Moraxella catarrhalis
    2. Gram Positive activity varies (4th generation is best)
      1. Best Fluoroquinolone coverage
        1. Moxifloxacin (strep activity 4-8 fold Levofloxacin)
        2. Trovafloxacin
        3. Levofloxacin (less active for Staph. and Strep.)
        4. Sparfloxacin (less active for Staph. and Strep.)
      2. Fluoroquinolones with minimal to no coverage
        1. First Generation Fluoroquinolones
        2. Second Generation Fluoroquinolones
      3. Bacteria
        1. Staphylococci
        2. Streptococci (Streptococcus Pneumoniae)
    3. Anaerobic Bacteria coverage
      1. Best Coverage
        1. Trovafloxacin
        2. Moxifloxacin (unlabeled use)
        3. Clinafloxacin (most potent against Anaerobes)
      2. Fluoroquinolones with no coverage
        1. First Generation Fluoroquinolones
        2. Second Generation Fluoroquinolones
    4. Atypical Bacteria coverage
      1. Bacteria
        1. Legionella pneumophila
        2. Chlamydia pneumoniae
        3. Mycoplasma pneumoniae
        4. Ureaplasma
      2. Best Fluoroquinolone coverage
        1. Moxifloxacin
        2. Levofloxacin
        3. Gemifloxacin
  9. Adverse Effects
    1. Interferes with cartilage growth in animals
      1. Avoid in children under age 18 years (however see caveat under contraindications as above)
    2. Nausea
    3. Taste disturbance
    4. Diarrhea
    5. Photosensitivity
    6. Pruritus or dermatitis
    7. Glucose effects in Diabetes Mellitus
      1. May result in Hypoglycemia and Hyperglycemia
    8. Tendinopathy (black box warning)
      1. Informed Consent regarding risk (and avoiding high impact activities) is recommended
      2. Onset typically within first 1-2 weeks of exposure, but may be delayed up to 90 days
      3. Achilles Tendon Rupture increased risk (3.2 cases per 1000 patient treatment years)
      4. Higher risk patients
        1. Age over 60 years
        2. Chronic Kidney Disease
        3. Concurrent Corticosteroid use (RR 46)
        4. Athletes
        5. Transplant recipients
      5. References
        1. Delaney in Herbert (2015) EM:Rap 15(9):11-2
        2. (2005) Clin Infect Dis 41: 144 [PubMed]
        3. (2002) BMJ 324:1306 [PubMed]
    9. QTc Prolongation (risk of Torsades de Pointes)
      1. Grepafloxacin pulled from U.S. market in 1999
      2. Also may occur with Sparfloxacin and Moxifloxacin
    10. Peripheral Neuropathy
      1. Potentially long-lasting complication with serious Disability (led to FDA warning in 2013)
      2. http://www.fda.gov/Drugs/DrugSafety/ucm365050.htm
    11. Other neurologic effects (3% of patients)
      1. Confusion or other mental status changes
        1. Most common in the elderly or those with decreased Renal Function
      2. Seizures (especially if concurrent NSAID use)
      3. Insomnia
      4. Hallucinations
      5. Headache
      6. Dizziness
      7. Tremors
  10. Drug Interactions
    1. Antiarrhythmics or Cisapride (risk QTc Prolongation)
    2. NSAIDs (risk of Seizure)
    3. Increases level of other medications
      1. Increased Anticoagulation effect with Coumadin
      2. Increased Cyclosporine (also risks nephrotoxicity)
      3. Increased Caffeine level
      4. Increased Theophylline levels
      5. Increased Riluzole levels
    4. Chelates with cations (decreased Quinolone absorption)
      1. Avoid these agents within 2 hours of Quinolone
      2. Antacids containing Magnesium, Aluminum or Calcium
      3. Iron Sulfate
      4. Zinc
      5. Calcium
      6. Didanosine
      7. Sucralfate
    5. Decreases Norfloxacin activity
      1. Chloramphenicol
      2. Nitrofurantoin
      3. Rifampin
      4. Tetracycline
  11. References
    1. Mandell (2000) Infectious Disease, Churchill, p. 576
    2. King (2000) Am Fam Physician 61(9):2741-8 [PubMed]
    3. O'Donnell (2000) Infect Dis Clin North Am 14(2):489-513 [PubMed]
    4. Oliphant (2002) Am Fam Physician 65(3):455-64 [PubMed]
    5. Owens (2000) Med Clin North Am 84(6):1447-69 [PubMed]

Quinolones (C0034428)

Definition (MSH) A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.
Concepts Organic Chemical (T109)
MSH D015363
English Ketoquinolines, Oxoquinolines, Quinolinones, Quinolones [Chemical/Ingredient], quinolone, quinolones, quinolinone, Quinolones
Swedish Kinoloner
Czech chinolinony, chinolony, sparfloxacin
Finnish Kinolonit
Russian KHINOLINONY, KHINOLONY, KETOKHINOLINONY, OKSOKHINOLINONY, КЕТОХИНОЛИНОНЫ, ОКСОХИНОЛИНОНЫ, ХИНОЛИНОНЫ, ХИНОЛОНЫ
Japanese オキソキノリン, キノリノン, キノロン, ケトキノリン
Italian Chetochinoline, Chinolinoni, Ossochinoline, Chinoloni
Croatian KINOLONI
Polish Chinolonu pochodne, Chinolinony
Norwegian Not Translated[Quinolones]
French Quinolinone, Quinolone
German Chinolinone, Chinolone, Ketochinoline, Oxochinoline
Portuguese Cetoquinolinas, Oxoquinolinas, Quinolinonas, Quinolonas
Spanish Cetoquinolinas, Oxoquinolinas, Quinolinonas, Quinolonas
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Fluoroquinolones (C0949665)

Definition (MSH) A group of QUINOLONES with at least one fluorine atom and a piperazinyl group.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D024841
Swedish Fluorokinoloner
Czech fluorochinolony
Finnish Fluorokinolonit
Russian FTORKHINOLONY, FLUOROKHINOLONY, ФЛУОРОХИНОЛОНЫ, ФТОРХИНОЛОНЫ
Croatian Not Translated[Fluoroquinolones]
English Fluoroquinolones [Chemical/Ingredient], fluoroquinolones, fluoroquinolone, Fluoroquinolones
Polish Fluorochinolonu pochodne
French Fluoroquinolones
German Fluorchinolone
Italian Fluorochinoloni
Portuguese Fluoroquinolonas
Spanish Fluoroquinolonas
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree